Loading stock…

QuidelOrtho Corporation (QDEL) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

QuidelOrtho Corporation

QDELMarket cap $0.86BPrice $12.6

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

Makes diagnostic tests that detect everything from flu and strep to pregnancy and heart conditions, running on machines found in hospitals and labs worldwide. Its rapid COVID tests once flew off shelves faster than any product in company history.

In Bastion Portfolios?

52W Return-55%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-6%2

Revenue Forecast

Rev CAGR (1y)-6%1

Rev CAGR (3y)-1%1

Rev CAGR (5y)+1%1

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2+97%10

EPS Growth Y+3+23%8

Quality

Margins

EBIT Margin1%2

Net Income Margin-39%1

Free Cash Flow Margin-8%2

Debt

Net Debt/EBITDA5.61

Efficiency

ROE-46%1

ROA-17%1

Earnings Stability11

GEAR+VERY WEAK3

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)137

P/E Ratio (Forward 3y)79

P/BV0.510

EV Multiples

EV/EBITDA Fwd78

EV/EBIT Fwd137

Yield

Free Cash Flow Yield-24.5%1

Dividend Yieldna–

Momentum

Short term

1 month return-10%2

3 month return-26%1

YTD return-56%1

Mid term

Price vs 52wHigh35%1

1 year return-55%1

Long term

3 year return-82%1

5 year return-91%1

Risk Shield

Price Risk

Beta1.23

Volatility92%1

Free Cash Flow

Free Cash Flow Margin-8%2

Free Cash Flow Yield-24.5%1

Quality

ROCE1%2

Earnings Stability11

Net Debt/EBITDA5.61

02Growth

Is it actually growing, and how fast?

QDELQuidelOrtho

Revenue FY25$2.8B

GROWTH RATING↗

VERY WEAK5 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-6%2

Revenue, next 1Y-6%1

Revenue, next 3Y, CAGR-1%1

Revenue, next 5Y, CAGR+1%1

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+97%10

EPS growth, FY28E+23%8

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue fell 6%/yr over the last 3 years, and it is still set to shrink 0.6%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 95% of companies worldwide.

Revenue fell 6%/yr over the last 3 years, behind 80% of companies worldwide.2/10

Revenue is set to shrink 0.6%/yr over the next 3 years, behind most of the market.1/10

Over five years revenue is set to grow 0.9%/yr, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business whose decline is easing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK1 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-10%2

3-month return-26%1

YTD return-56%1

MID & LONG-TERM▾SCORE

% of 52-week high35%1

1-year return-55%1

3-year return-82%1

5-year return-91%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-82% over three years and -91% over five), behind 90% of the market.

It's down 55% over the past year, now 65% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-10%), over three months (-26%) and so far this year (-56%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on QuidelOrtho Corporation. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

QDELQuidelOrtho

Revenue FY25$2.8B

GROWTH RATING↗

VERY WEAK5 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-6%2

Revenue, next 1Y-6%1

Revenue, next 3Y, CAGR-1%1

Revenue, next 5Y, CAGR+1%1

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+97%10

EPS growth, FY28E+23%8

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue fell 6%/yr over the last 3 years, and it is still set to shrink 0.6%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 95% of companies worldwide.

Revenue fell 6%/yr over the last 3 years, behind 80% of companies worldwide.2/10

Revenue is set to shrink 0.6%/yr over the next 3 years, behind most of the market.1/10

Over five years revenue is set to grow 0.9%/yr, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business whose decline is easing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK1 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-10%2

3-month return-26%1

YTD return-56%1

MID & LONG-TERM▾SCORE

% of 52-week high35%1

1-year return-55%1

3-year return-82%1

5-year return-91%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-82% over three years and -91% over five), behind 90% of the market.

It's down 55% over the past year, now 65% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-10%), over three months (-26%) and so far this year (-56%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on QuidelOrtho Corporation. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community